Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$376.71M$376.71M+42.2% vs Q1 2025 Net Income$150.05M$150.05M+27.1% vs Q1 2025 EPS Diluted$1.22$1.22+31.2% vs Q1 2025 Operating Income$184,517,000+30.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$176,337,000+15.0% Margins · derivedOperating margin49.0%−4.5 pt vs Q1 2025
Net margin39.8%−4.8 pt vs Q1 2025
ended Mar 31, 2026 · filed May 11, 2026 · 41 d after period end